Aclaris Therapeutics Stock In The News
| ACRS Stock | USD 4.32 0.36 9.09% |
Our overall analysis of Aclaris Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Aclaris Therapeutics. The specific impact of Aclaris Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Aclaris Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Aclaris Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Aclaris Therapeutics Backtesting and Aclaris Therapeutics Hype Analysis. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.
Aclaris |
Aclaris Therapeutics Today Top News and Investor Outlook
Aclaris Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Aclaris and other traded companies coverage with news coverage. We help investors stay connected with Aclaris headlines for the 22nd of November to make an informed investment decision based on correlating the impacts of news items on Aclaris Stock performance. Please note that trading solely based on the Aclaris Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Aclaris Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Aclaris earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Aclaris Therapeutics that are available to investors today. That information is available publicly through Aclaris media outlets and privately through word of mouth or via Aclaris internal channels. However, regardless of the origin, that massive amount of Aclaris data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Aclaris Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Aclaris Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Aclaris Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Aclaris Therapeutics alpha.
Aclaris Largest EPS Surprises
Earnings surprises can significantly impact Aclaris Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-02-25 | 2020-12-31 | -0.27 | -0.3 | -0.03 | 11 | ||
2024-08-07 | 2024-06-30 | -0.2 | -0.15 | 0.05 | 25 | ||
2024-05-07 | 2024-03-31 | -0.29 | -0.24 | 0.05 | 17 | ||
2022-08-03 | 2022-06-30 | -0.36 | -0.31 | 0.05 | 13 | ||
2020-11-04 | 2020-09-30 | -0.3 | -0.25 | 0.05 | 16 | ||
2020-05-07 | 2020-03-31 | -0.32 | -0.37 | -0.05 | 15 |
Aclaris Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Aclaris Therapeutics Stock. Current markets are slightly bullish. About 58% of major world exchanges and indexes are currently up. See today's market update for more information.
21st of November 2024
Acquisition by Leonard Braden Michael of 206025 shares of Aclaris Therapeutics at 1.2443 s... at bizjournals.com
19th of November 2024
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging ... at benzinga.com
18th of November 2024
Aclaris Therapeutics Announces 80 Million Private Placement at gurufocus.com
8th of November 2024
Aclaris Therapeutics Third Quarter 2024 Earnings Misses Expectations at simplywall.st
6th of November 2024
Aclaris Therapeutics Inc Reports Q3 2024 Revenue at 4.35M, EPS Loss of 0.11, Misses Estima... at gurufocus.com
1st of November 2024
Disposition of 9467 shares by Walker Neal of Aclaris Therapeutics subject to Rule 16b-3 at MacroaxisInsider
1st of October 2024
Disposition of 9467 shares by Walker Neal of Aclaris Therapeutics subject to Rule 16b-3 at MacroaxisInsider
17th of September 2024
Aclaris Therapeutics, Inc. Receives Average Rating of Hold from Analysts at thelincolnianonline.com
30th of August 2024
Disposition of 9466 shares by Walker Neal of Aclaris Therapeutics subject to Rule 16b-3 at Walker Neal
29th of August 2024
Aclaris Therapeutics Stock Crosses Below 50 Day Moving Average of 1.24 - MarketBeat at news.google.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Aclaris Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Aclaris Therapeutics' short interest history, or implied volatility extrapolated from Aclaris Therapeutics options trading.
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.